ACT Genomics Expands ACTMonitor® Breast to 10 Genes, Adding AKT1 and PTEN Biomarkers

[Taipei, Taiwan | February 13, 2026] — ACT Genomics Co., Ltd.(“ACT Genomics”) today announced an update to ACTMonitor^® Breast, expanding the assay to a 10-gene panel with the addition of AKT1 and PTEN biomarkers. This enhancementis designed to broaden molecular insights available to clinicians andlaboratories supporting breast cancer monitoring and care.

“By adding AKT1 and PTEN, we’re strengthening ACTMonitor^® Breast’s ability to capture clinically relevant genomic signals within a streamlined panel,” said Dr. Hua Chien Chen, CEO at ACT Genomics. “Our goal is to keep improving the assay in ways that are meaningful for real-world clinical workflows.”

What’s new in ACTMonitor^® Breast:

• Expanded coverage: Updated from 8 to 10 genes
• New additions: AKT1 and PTEN

ACTMonitor^® Breast is part of ACT Genomics’ commitment to continuously improving molecular testingsolutions with updates informed by scientific and clinical developments.

Availability

The updated ACTMonitor^® Breast (10-gene) panel will be introduced in phases. Availability may vary by institutionand region based on individual service agreements, and rollout will occurgradually as implementation is completed across participating sites. For ordering details and timeline by account, please contact ACT Genomics or your designated representative.

Important Note: ACTMonitor^® Breast is intended for use by qualified healthcare professionalsand laboratories. Test availability, intended use, and regulatory requirements may vary by region.

‍